Normalization of serum alpha fetoprotein after direct acting antivirals in hepatitis C patients lowers hepatocellular carcinoma risk
Guardat en:
| Publicat a: | Scientific Reports (Nature Publisher Group) vol. 15, no. 1 (2025), p. 32312-32321 |
|---|---|
| Autor principal: | |
| Altres autors: | , |
| Publicat: |
Nature Publishing Group
|
| Matèries: | |
| Accés en línia: | Citation/Abstract Full Text Full Text - PDF |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3245813407 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 2045-2322 | ||
| 024 | 7 | |a 10.1038/s41598-025-14861-9 |2 doi | |
| 035 | |a 3245813407 | ||
| 045 | 2 | |b d20250101 |b d20251231 | |
| 084 | |a 274855 |2 nlm | ||
| 100 | 1 | |a Lin, Cheng-Kuan |u Division of Gastroenterology and Hepatology, Department of Internal Medicine, Far Eastern Memorial Hospital, No. 21, Nanya South Road, Section 2, Banqiao District, 220216, New Taipei City, Taiwan (ROR: https://ror.org/019tq3436) (GRID: grid.414746.4) (ISNI: 0000 0004 0604 4784) | |
| 245 | 1 | |a Normalization of serum alpha fetoprotein after direct acting antivirals in hepatitis C patients lowers hepatocellular carcinoma risk | |
| 260 | |b Nature Publishing Group |c 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a The elevation of serum alpha-fetoprotein (AFP) is frequently observed in patients with chronic hepatitis C (CHC). In most cases, the level decreased after antiviral treatment. This study investigated the relationship between post-treatment AFP normalization and the risk of hepatocellular carcinoma (HCC) in CHC patients without baseline HCC. A total of 483 patients treated with sofosbuvir-based direct-acting antivirals (DAAs) were enrolled and followed for a mean duration of 38.8 months. The mean age was 59.6 years, and 27.1% of patients had liver cirrhosis. The sustained virological response (SVR) rate was 98.6%. The pre-treatment AFP levels > 7 ng/mL, > 10 ng/mL, and > 15 ng/mL were observed in 25.4%, 18.8%, and 9.7% of patients, respectively. By 12 weeks post-treatment, 86.2% of patients had AFP levels < 7 ng/mL. During follow-up, 5.4% of patients developed HCC. The independent risk factors for HCC included age ≥ 65 years, liver cirrhosis, and post-treatment AFP > 7 ng/mL. The hazard ratio of HCC was 0.03 (95% CI: 0.01–0.3, P < 0.01) in the “Normalization” group, compared to the “Persistent elevation” group. The hazard ratio was 0.28 (95% CI: 0.1–0.73, P = 0.01) in the “Stable normal” group, compared to the “Elevation” group. The findings suggest that normalization of AFP levels or stable normal levels after treatment are associated with a reduced risk of HCC. | |
| 653 | |a Patients | ||
| 653 | |a α-Fetoprotein | ||
| 653 | |a Antiviral drugs | ||
| 653 | |a Cirrhosis | ||
| 653 | |a Diabetes | ||
| 653 | |a Hepatocellular carcinoma | ||
| 653 | |a Hepatitis C | ||
| 653 | |a Age | ||
| 653 | |a Risk factors | ||
| 653 | |a Hepatitis | ||
| 653 | |a Liver cirrhosis | ||
| 653 | |a Females | ||
| 653 | |a Liver cancer | ||
| 653 | |a Fatty liver | ||
| 653 | |a Genotype & phenotype | ||
| 653 | |a Liver | ||
| 653 | |a Risk reduction | ||
| 653 | |a Antiviral agents | ||
| 653 | |a Interferon | ||
| 653 | |a Social | ||
| 700 | 1 | |a Wang, Ssu-Han |u Division of Gastroenterology and Hepatology, Department of Internal Medicine, Far Eastern Memorial Hospital, No. 21, Nanya South Road, Section 2, Banqiao District, 220216, New Taipei City, Taiwan (ROR: https://ror.org/019tq3436) (GRID: grid.414746.4) (ISNI: 0000 0004 0604 4784) | |
| 700 | 1 | |a Lee, Tzong-Hsi |u Division of Gastroenterology and Hepatology, Department of Internal Medicine, Far Eastern Memorial Hospital, No. 21, Nanya South Road, Section 2, Banqiao District, 220216, New Taipei City, Taiwan (ROR: https://ror.org/019tq3436) (GRID: grid.414746.4) (ISNI: 0000 0004 0604 4784) | |
| 773 | 0 | |t Scientific Reports (Nature Publisher Group) |g vol. 15, no. 1 (2025), p. 32312-32321 | |
| 786 | 0 | |d ProQuest |t Science Database | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3245813407/abstract/embedded/J7RWLIQ9I3C9JK51?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/3245813407/fulltext/embedded/J7RWLIQ9I3C9JK51?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3245813407/fulltextPDF/embedded/J7RWLIQ9I3C9JK51?source=fedsrch |